Figure 2. IL-10⁺ B cell were enriched with the CD19⁺CD24⁺CD38⁺ B cells population.

(A) The percentages of CD19⁺ B cells in PBMCs had no different among FIBma patients, IBCa patients and health individuals (5.89 ± 2.44%, 5.31 ± 3.23%, and 4.75 ± 2.16%, respectively). (B) A higher level of IL-10 (2.31 ± 1.01%) in IBCa patients compared with FIBma patients (1.12 ± 0.41%) (P = 0.046). (C,D) In our early report, CD19⁺CD24⁺CD38⁺ B cell was identified as regulatory B cells in breast cancer¹². So, to identify the phenotype of CD19⁺L-10⁺ B cells in PBMCs of IBCa, stained with CD24 and CD38 and analyzed by flow cytometry. A significantly higher percentage of CD24⁺CD38⁺ in the CD19⁺IL-10⁺ group (39.18 ± 5.98%) compared to that in the CD19⁺IL-10⁻ group (8.87 ± 4.08%) (P = 0.001). (E) The higher level of IL-10 secreted by CD19⁺CD24⁺CD38⁺ B lymphocytes (39.18 ± 18.91%) than CD19⁺CD24⁻CD38⁺ B cells (20.72 ± 13.01%) or CD19⁺CD24⁺CD38⁻ B cells (20.48 ± 13.46%) (P = 0.023, P = 0.0231).